GOLDSTONE ASIA PHARM issued a profit forecast, expecting a net profit of RMB 86.6055 million to RMB 107 million in the first three quarters, a year-on-year increase of 48.99% to 83.95%

GOLDSTONE ASIA PHARM expects its net profit for the first three quarters of 2025 to be between 86.6055 million yuan and 107 million yuan, a year-on-year increase of 48.99% to 83.95%. The net profit after deducting non-recurring gains and losses is expected to be between 69.1279 million yuan and 89.4488 million yuan, a year-on-year increase of 32.83% to 71.88%. The company has achieved a year-on-year decrease in period expenses through budget optimization and cost control measures, with overall business developing steadily, and both revenue and gross profit in the new materials and machinery business segments showing year-on-year improvement